$CRBP
Corbus Pharmaceuticals Holdings, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039960 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.940M $3.940M $4.840M
YoY Change -27.82% -18.6% -13.14%
% of Gross Profit
Research & Development $6.550M $4.249M $2.500M
YoY Change 59.45% 69.97% -77.81%
% of Gross Profit
Depreciation & Amortization $152.8K $158.3K $192.1K
YoY Change -19.91% -17.56% -27.75%
% of Gross Profit
Operating Expenses $9.488M $8.189M $7.340M
YoY Change 15.97% 11.57% -56.41%
Operating Profit -$9.488M -$8.189M -$12.34M
YoY Change 15.97% -33.64%
Interest Expense -$780.0K -$777.5K -$700.2K
YoY Change 15.05% 11.04% 233.89%
% of Operating Profit
Other Income/Expense, Net -$565.3K $594.9K -$208.7K
YoY Change -5.82% -385.05% -8.32%
Pretax Income -$10.05M -$8.784M -$13.25M
YoY Change 14.44% -33.7% -22.69%
Income Tax
% Of Pretax Income
Net Earnings -$10.05M -$8.784M -$13.25M
YoY Change 14.48% -33.7% -22.69%
Net Earnings / Revenue
Basic Earnings Per Share -$2.27 -$2.05 -$3.18
Diluted Earnings Per Share -$2.27 $2.05 -$105.8K
COMMON SHARES
Basic Shares Outstanding 4.424M 4.215M 125.3M
Diluted Shares Outstanding 4.424M 4.278M 4.170M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.70M $36.57M $73.30M
YoY Change -56.67% -50.12% -31.14%
Cash & Equivalents $11.25M $8.349M $21.78M
Short-Term Investments $17.50M $28.22M $47.53M
Other Short-Term Assets $2.500M $1.708M $1.935M
YoY Change 123.49% -11.71% -29.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.21M $38.27M $75.24M
YoY Change -53.66% -49.13% -32.57%
LONG-TERM ASSETS
Property, Plant & Equipment $1.121M $1.274M $6.247M
YoY Change -37.67% -79.61% -26.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $201.3K $211.9K $581.6K
YoY Change 51.27% -63.56% 1.59%
Total Long-Term Assets $5.077M $5.449M $6.829M
YoY Change -21.68% -20.2% -24.37%
TOTAL ASSETS
Total Short-Term Assets $31.21M $38.27M $75.24M
Total Long-Term Assets $5.077M $5.449M $6.829M
Total Assets $36.28M $43.72M $82.07M
YoY Change -50.86% -46.72% -31.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.714M $1.506M $1.987M
YoY Change 243.0% -24.21% 5.77%
Accrued Expenses $7.546M $6.419M $5.924M
YoY Change 56.1% 8.35% -63.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $17.85M $7.016M $7.586M
YoY Change 80.6% -7.51% 7286.84%
Total Short-Term Liabilities $31.54M $16.39M $15.63M
YoY Change 80.56% 4.84% -16.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $11.32M $11.61M
YoY Change -100.0% -2.52% -36.8%
Other Long-Term Liabilities $44.41K $22.21K $5.355M
YoY Change 100.0% -99.59% -18.12%
Total Long-Term Liabilities $44.41K $11.34M $16.97M
YoY Change -99.53% -33.16% -31.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.54M $16.39M $15.63M
Total Long-Term Liabilities $44.41K $11.34M $16.97M
Total Liabilities $35.97M $34.20M $32.60M
YoY Change 12.82% 4.93% -25.32%
SHAREHOLDERS EQUITY
Retained Earnings -$428.7M -$418.6M
YoY Change 12.45%
Common Stock $442.00 $442.00
YoY Change -96.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $311.0K $9.521M $49.47M
YoY Change
Total Liabilities & Shareholders Equity $36.28M $43.72M $82.07M
YoY Change -50.86% -46.72% -31.96%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$10.05M -$8.784M -$13.25M
YoY Change 14.48% -33.7% -22.69%
Depreciation, Depletion And Amortization $152.8K $158.3K $192.1K
YoY Change -19.91% -17.56% -27.75%
Cash From Operating Activities -$7.170M -$7.800M -$12.23M
YoY Change -1.04% -36.22% -30.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.89M $8.807M -$18.70M
YoY Change -282.37% -147.11% 42.69%
Cash From Investing Activities $10.89M $8.807M -$18.70M
YoY Change -282.37% -147.11% 42.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -820.0K 17.69K -330.1K
YoY Change 640.67% -105.36% 31.08%
NET CHANGE
Cash From Operating Activities -7.170M -7.800M -12.23M
Cash From Investing Activities 10.89M 8.807M -18.70M
Cash From Financing Activities -820.0K 17.69K -330.1K
Net Change In Cash 2.900M 1.025M -31.26M
YoY Change -121.76% -103.28% 1.21%
FREE CASH FLOW
Cash From Operating Activities -$7.170M -$7.800M -$12.23M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$7.170M -$7.800M -$12.23M
YoY Change -1.04% -36.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001595097
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37348
dei Entity Registrant Name
EntityRegistrantName
Corbus Pharmaceuticals Holdings, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4348039
dei Entity Address Address Line1
EntityAddressAddressLine1
500 River Ridge Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Norwood
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02062
dei City Area Code
CityAreaCode
(617)
dei Local Phone Number
LocalPhoneNumber
963-0100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CRBP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4423683
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8349346
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
28216560
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
42194296
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1515616
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
791616
CY2023Q2 us-gaap Assets Current
AssetsCurrent
38273997
CY2022Q4 us-gaap Assets Current
AssetsCurrent
60181102
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1273602
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3486416
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3884252
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
211943
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155346
CY2023Q2 us-gaap Assets
Assets
43723383
CY2022Q4 us-gaap Assets
Assets
66311940
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
51157
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
353323
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1505734
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173963
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6418803
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
36868
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
36868
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1357240
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1280863
CY2023Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
7016096
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2795669
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16385898
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12639938
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11319365
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2023Q2 us-gaap Entertainment License Agreement For Program Material Liability Noncurrent
EntertainmentLicenseAgreementForProgramMaterialLiabilityNoncurrent
2500000
CY2022Q4 us-gaap Entertainment License Agreement For Program Material Liability Noncurrent
EntertainmentLicenseAgreementForProgramMaterialLiabilityNoncurrent
0
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3975329
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4675354
CY2023Q2 us-gaap Liabilities
Liabilities
34202797
CY2022Q4 us-gaap Liabilities
Liabilities
33321923
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4422741
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4422741
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171297
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171297
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
442
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
417
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
428153252
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425196359
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-418609320
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392080667
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23788
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-126092
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9520586
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43723383
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66311940
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4248705
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2499642
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17637048
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5785878
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3940286
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4840368
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7848968
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10071291
CY2023Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2022Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5000000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5000000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8188991
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12340010
us-gaap Operating Expenses
OperatingExpenses
25486016
us-gaap Operating Expenses
OperatingExpenses
20857169
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8188991
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12340010
us-gaap Operating Income Loss
OperatingIncomeLoss
-25486016
us-gaap Operating Income Loss
OperatingIncomeLoss
-20857169
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
182657
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-208683
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
412164
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-402034
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-775586
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-490339
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1453608
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-949248
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1921
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-209856
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1193
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-477679
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
594850
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-908878
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1042637
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1828961
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-8783841
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-13248888
us-gaap Profit Loss
ProfitLoss
-26528653
us-gaap Profit Loss
ProfitLoss
-22686130
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.18
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.44
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4277701
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4277701
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170464
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4170464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4229894
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4229894
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170255
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4170255
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8783841
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13248888
us-gaap Net Income Loss
NetIncomeLoss
-26528653
us-gaap Net Income Loss
NetIncomeLoss
-22686130
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
44681
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
50373
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
102304
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-56875
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44681
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
50373
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
102304
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-56875
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8739160
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13198515
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26426349
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22743005
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
16458952
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4404
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
102419
CY2023Q2 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
875000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
823375
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44681
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8783841
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9520586
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61155284
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1513089
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50373
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13248888
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
49469858
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4404
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
102419
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
875000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129745
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1849754
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-102304
us-gaap Net Income Loss
NetIncomeLoss
-26528653
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
9520586
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3104835
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-56875
us-gaap Net Income Loss
NetIncomeLoss
-22686130
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
49469858
us-gaap Net Income Loss
NetIncomeLoss
-26528653
us-gaap Net Income Loss
NetIncomeLoss
-22686130
us-gaap Share Based Compensation
ShareBasedCompensation
1849754
us-gaap Share Based Compensation
ShareBasedCompensation
3104835
us-gaap Depreciation And Amortization
DepreciationAndAmortization
340213
us-gaap Depreciation And Amortization
DepreciationAndAmortization
387803
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
278677
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-661398
crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
4388
crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-631213
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
430367
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
357464
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-1528
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-118671
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21235
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
698679
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-622737
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
56598
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-57780
crbp Decrease In Operating Lease Right Of Use Asset
DecreaseInOperatingLeaseRightOfUseAsset
-397836
crbp Decrease In Operating Lease Right Of Use Asset
DecreaseInOperatingLeaseRightOfUseAsset
-351033
crbp Increase In Other Long Term Liabilities
IncreaseInOtherLongTermLiabilities
-2500000
crbp Increase In Other Long Term Liabilities
IncreaseInOtherLongTermLiabilities
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-663843
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-426868
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
419551
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5376890
crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-623648
crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-553125
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22915237
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22844404
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
23930480
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
66366447
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
38287670
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
90637466
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13449
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8100
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14357190
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24265670
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
302166
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
657233
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236568
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
29724
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-95322
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-657233
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8653369
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
764033
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17672615
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9019246
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26440565
us-gaap Interest Paid Net
InterestPaidNet
1321575
us-gaap Interest Paid Net
InterestPaidNet
887428
crbp Stock Subscription Receivable
StockSubscriptionReceivable
40928
crbp Stock Subscription Receivable
StockSubscriptionReceivable
0
crbp Issuance Of Common Stock For Conversion Of Convertible Debt
IssuanceOfCommonStockForConversionOfConvertibleDebt
875000
crbp Issuance Of Common Stock For Conversion Of Convertible Debt
IssuanceOfCommonStockForConversionOfConvertibleDebt
0
crbp Write Off Of Fully Depreciated Property And Equipment
WriteOffOfFullyDepreciatedPropertyAndEquipment
178492
crbp Write Off Of Fully Depreciated Property And Equipment
WriteOffOfFullyDepreciatedPropertyAndEquipment
0
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF OPERATIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internally developing pipeline includes CRB-701, a next generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The Company has also developed CRB-913, an endocannabinoid small molecule drug, for the treatment of obesity and is seeking partners to fund further development. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable, and it may never achieve profitability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation. In the opinion of management of the Company, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include only normal recurring adjustments) necessary to present fairly, in all material respects, the condensed consolidated financial position of the Company as of June 30, 2023 and the results of its operations and changes in stockholders’ equity for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six months ended June 30, 2023 and 2022. The December 31, 2022 condensed consolidated balance sheet was derived from audited financial statements. The Company prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (the “SEC”) for interim reporting. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP") have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, filed on March 7, 2023 (the “2022 Annual Report”). The results of operations for such interim periods are not necessarily indicative of the operating results for the full fiscal year.</span></p>
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-418609000
CY2023Q2 crbp Cash And Cash Equivalents And Marketable Debt Securities
CashAndCashEquivalentsAndMarketableDebtSecurities
36566000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-30
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">process of preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, and the valuation of warrants (see Note 9 and Note 14) and the derivative liability associated with the K2 Loan and Security Agreement (see Note 15).</span></p>
CY2023Q2 us-gaap Cash
Cash
1728888
CY2022Q4 us-gaap Cash
Cash
3805156
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6620458
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13197559
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8349346
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
669900
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9019246
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17672615
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may, from time to time, have cash in its U.S. banks in excess of Federal Deposit Insurance Corporation insurance limits and in its foreign banks in excess of their local insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</span></p>
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8783841
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13248888
us-gaap Net Income Loss
NetIncomeLoss
-26528653
us-gaap Net Income Loss
NetIncomeLoss
-22686130
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4277701
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4229894
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170255
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.44
CY2023Q2 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
28240348000
CY2023Q2 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000
CY2023Q2 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-23797000
CY2023Q2 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
28216560000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
28240348000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
28216560000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
28240348000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
28216560000
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
42320040
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-125744
CY2022Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
42194296
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
42320040000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
42194296000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
42320040000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
42194296000
CY2021Q2 crbp Licence Issuance Fee
LicenceIssuanceFee
750000
crbp Subleases Income
SubleasesIncome
110266
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
134241
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4528546
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4707038
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3254944
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3093223
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1273602
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2023Q2 us-gaap Depreciation
Depreciation
158343
CY2022Q2 us-gaap Depreciation
Depreciation
192084
us-gaap Depreciation
Depreciation
340213
us-gaap Depreciation
Depreciation
387803
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
853956
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1747447
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1794889
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1688145
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6084437
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
751868
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5332569
crbp Sublease Agreement Description
SubleaseAgreementDescription
Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and ends October 31, 2026. The Company notes sublease income of $59,133 and $55,133 for the three months ended June 30, 2023 and 2022, respectively and $114,266 and $110,266 for the six months ended June 30, 2023 and 2022, respectively was recognized and offset against rent expense.
CY2021Q3 crbp Sublease Area
SubleaseArea
12112
CY2021Q3 crbp Sublease Area Total
SubleaseAreaTotal
30023
CY2023Q2 crbp Subleases Income
SubleasesIncome
59133
CY2022Q2 crbp Subleases Income
SubleasesIncome
55133
crbp Subleases Income
SubleasesIncome
114266
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
279585
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
291697
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
252333
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
957856
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
970000
us-gaap Interest Expense Debt
InterestExpenseDebt
1907000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
698000
us-gaap Interest Expense Debt
InterestExpenseDebt
1382000
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
19125000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2954390
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2954390
CY2023Q2 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
2164851
CY2022Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
1734485
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18335461
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18780095
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
7016096
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2795669
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11319365
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2827686
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
17887314
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
20715000
CY2023Q2 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
2694611
CY2022Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
2137317
CY2023Q2 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
758699
CY2022Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
247500
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1570376
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2224951
CY2023Q2 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
282846
CY2022Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
473376
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1112271
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
916108
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6418803
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4422741
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4422741
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171297
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171297
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
823375
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1513089
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1849754
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3104835
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
823375
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1513089
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1849754
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3104835
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
617996
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
88.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
285733
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
43836
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
120909
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
67.78
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
738984
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M26D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20769766
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
388412
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
106.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y6M25D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5252474
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
671776
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
70.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17407765
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
25659
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4317
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.26
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
21342
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.71
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
75498
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M24D
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
36868
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
36868
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
36868
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
36868

Files In Submission

Name View Source Status
0000950170-23-039960-index-headers.html Edgar Link pending
0000950170-23-039960-index.html Edgar Link pending
0000950170-23-039960.txt Edgar Link pending
0000950170-23-039960-xbrl.zip Edgar Link pending
crbp-20230630.htm Edgar Link pending
crbp-20230630.xsd Edgar Link pending
crbp-ex31_1.htm Edgar Link pending
crbp-ex31_2.htm Edgar Link pending
crbp-ex32_1.htm Edgar Link pending
crbp-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
crbp-20230630_cal.xml Edgar Link unprocessable
crbp-20230630_def.xml Edgar Link unprocessable
crbp-20230630_lab.xml Edgar Link unprocessable
crbp-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crbp-20230630_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending